Indacaterol
| Clinical data | |
|---|---|
| Trade names | Onbrez, Arcapta | 
| AHFS/Drugs.com | International Drug Names | 
| License data | 
  | 
| Pregnancy category  | 
  | 
| Routes of administration  | Inhalation | 
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
  | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.218.577 | 
| Chemical and physical data | |
| Formula | C24H28N2O3 | 
| Molar mass | 392.499 g·mol−1 | 
| 3D model (JSmol) | |
  | |
  | |
| (what is this?) (verify) | |
Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered through a dry powder inhaler.